norfloxacin has been researched along with Hepatorenal Syndrome in 3 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Hepatorenal Syndrome: Functional KIDNEY FAILURE in patients with liver disease, usually LIVER CIRRHOSIS or portal hypertension (HYPERTENSION, PORTAL), and in the absence of intrinsic renal disease or kidney abnormality. It is characterized by intense renal vasculature constriction, reduced renal blood flow, OLIGURIA, and sodium retention.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Norfloxacin is highly effective in preventing spontaneous bacterial peritonitis recurrence in cirrhosis, but its role in the primary prevention of this complication is uncertain." | 5.12 | Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. ( Arroyo, V; Fernández, J; Ginès, P; Monfort, D; Montoliu, S; Navasa, M; Pardo, A; Planas, R; Quintero, E; Soriano, G; Such, J; Vargas, V; Vila, C, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Salerno, F | 1 |
| La Mura, V | 1 |
| Fernández, J | 1 |
| Navasa, M | 1 |
| Planas, R | 1 |
| Montoliu, S | 1 |
| Monfort, D | 1 |
| Soriano, G | 1 |
| Vila, C | 1 |
| Pardo, A | 1 |
| Quintero, E | 1 |
| Vargas, V | 1 |
| Such, J | 1 |
| Ginès, P | 1 |
| Arroyo, V | 1 |
| Runyon, BA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Asymptomatic Spontaneous Bacterial Peritonitis in Patients With Decompensated Liver Cirrhosis in Upper Egypt : A Prospective Hospital Based Study[NCT03163745] | 70 participants (Actual) | Observational | 2019-03-11 | Completed | |||
| Comparison of Daily Norfloxacin Versus Weekly Ciprofloxacin for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients[NCT01542801] | Phase 4 | 124 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for norfloxacin and Hepatorenal Syndrome
| Article | Year |
|---|---|
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Double-Blind Method; Female; Hepatorenal Syndro | 2007 |
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Double-Blind Method; Female; Hepatorenal Syndro | 2007 |
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Double-Blind Method; Female; Hepatorenal Syndro | 2007 |
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Double-Blind Method; Female; Hepatorenal Syndro | 2007 |
2 other studies available for norfloxacin and Hepatorenal Syndrome
| Article | Year |
|---|---|
Treatment of Spontaneous Bacterial Peritonitis.
Topics: Age Factors; Albumins; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ascites; Bilirubin; Drug Resis | 2015 |
A pill a day can improve survival in patients with advanced cirrhosis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Norflo | 2007 |